GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Think AstraZeneca (AZN.L), GSK (GSK.L), Rolls-Royce (RR.L) and Lloyds (LLOY.L). Even the London Stock Exchange Group (LSEG.L) uses it! Covering human resources, financials and planning, Workday helps ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
TipRanks on MSN1d
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback